[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE415175T1 - Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck - Google Patents

Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck

Info

Publication number
ATE415175T1
ATE415175T1 AT03729747T AT03729747T ATE415175T1 AT E415175 T1 ATE415175 T1 AT E415175T1 AT 03729747 T AT03729747 T AT 03729747T AT 03729747 T AT03729747 T AT 03729747T AT E415175 T1 ATE415175 T1 AT E415175T1
Authority
AT
Austria
Prior art keywords
hypertension
lung
kidney disease
ace2
treat heart
Prior art date
Application number
AT03729747T
Other languages
English (en)
Inventor
Joseph M Penninger
Michael Crackower
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Application granted granted Critical
Publication of ATE415175T1 publication Critical patent/ATE415175T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Environmental Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
AT03729747T 2002-06-19 2003-06-19 Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck ATE415175T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38970902P 2002-06-19 2002-06-19

Publications (1)

Publication Number Publication Date
ATE415175T1 true ATE415175T1 (de) 2008-12-15

Family

ID=30000461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729747T ATE415175T1 (de) 2002-06-19 2003-06-19 Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck

Country Status (14)

Country Link
US (3) US7794707B2 (de)
EP (3) EP2332582B1 (de)
JP (1) JP4598518B2 (de)
CN (2) CN101961493A (de)
AT (1) ATE415175T1 (de)
AU (1) AU2003240331B2 (de)
CA (1) CA2489873C (de)
CY (1) CY1108829T1 (de)
DE (1) DE60324925D1 (de)
DK (2) DK1515752T3 (de)
ES (3) ES2443305T3 (de)
PT (2) PT2332582E (de)
SI (2) SI1515752T1 (de)
WO (1) WO2004000367A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2332582E (pt) * 2002-06-19 2014-01-28 Apeiron Biologics Ag Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
EP1723962A1 (de) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Gebrauch der Hemmnisse des Renin-angiotensinsystems für die Behandlung der Lungenverletzungen
GB0511279D0 (en) * 2005-06-02 2005-07-13 Univ Warwick Assay
WO2008066770A2 (en) * 2006-11-22 2008-06-05 University Of Florida Research Foundation, Inc. Ace2 activator compounds and methods of use thereof
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
AT506258A1 (de) 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
EP2077119A1 (de) 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
EP3058074B1 (de) 2013-10-18 2019-02-20 Trustees Of The University Of Pennsylvania Orale verabreichung des angiotensin-konvertierenden enzyms 2 (ace2) oder von in pflanzenzellen biogekapseltem angiotensin-(1-7)
CA3082610A1 (en) 2017-11-29 2019-06-06 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2019136318A2 (en) 2018-01-05 2019-07-11 Platelet Biogenesis, Inc. Compositions and methods for producing megakaryocytes
CN108660205A (zh) * 2018-07-04 2018-10-16 刘城 一种糖尿病遗传风险评估试剂盒及其运用
CN110577588B (zh) * 2019-09-29 2020-12-29 苏州大学 一种凹耳蛙免疫调节肽及其应用
CN111087445B (zh) * 2019-10-14 2021-08-24 浙江大学 一种用于ace2活性检测的质谱探针及其制备方法和应用
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021197501A1 (zh) * 2020-04-02 2021-10-07 创观（苏州）生物科技有限公司 病毒不易感动物
EP4132653A4 (de) * 2020-04-11 2024-05-22 Geneticure Inc. Genetisches verfahren zur diagnose und behandlung von prä- und postcoronavirusinfektionen
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
JP7563940B2 (ja) * 2020-10-22 2024-10-08 シスメックス株式会社 呼吸器感染症に関する情報の取得方法、バイオマーカーの測定値のモニタリング方法、試薬キット、呼吸器感染症に関する情報の取得装置及びコンピュータプログラム
EP4011387A1 (de) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Überlegene neutralisierung von sars-cov-2 durch deglykosyliertes, humanes angiotensin konvertierendes enzym 2
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
US20240358008A1 (en) * 2021-08-31 2024-10-31 New York University COMPOSITIONS AND METHODS FOR SWITCHING ANTIBIOTIC RESISTANCE MARKERS PROGRESSIVELY FOR INTEGRATION (mSwAP-In)
EP4147702A1 (de) 2021-09-13 2023-03-15 Medizinische Universität Graz Neue kombination von heparin und ace2-decoys für die behandlung von covid-19
WO2023102156A1 (en) 2021-12-03 2023-06-08 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same
WO2023144625A2 (en) * 2022-01-27 2023-08-03 The Chinese University Of Hong Kong Enhanced hace2-based neutralizing agents against sars-cov-2 infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5643873A (en) 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US5753226A (en) 1995-04-11 1998-05-19 The Trustees Of The University Of Pennsylvania Methods of enhancing epithelial cell proliferation
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US6224584B1 (en) 1997-01-14 2001-05-01 Eclipse Surgical Technologies, Inc. Therapeutic and diagnostic agent delivery
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5792851A (en) 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
US5851788A (en) 1997-01-31 1998-12-22 The Burnham Institute Nucleic acid encoding a family of acetyl-coenzyme-A transporter proteins, and products related thereto
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US5997509A (en) 1998-03-06 1999-12-07 Cornell Research Foundation, Inc. Minimally invasive gene therapy delivery device and method
TR200103094T2 (tr) 1999-04-30 2002-03-21 Millennium Pharmaceuticals, Inc. ACE-2 inhibe eden bileçikler ve bunlarìn kullanìm y”ntemi
MXPA02003924A (es) 1999-10-21 2002-10-23 Ciba Sc Holding Ag Proceso para la preparacion de derivados de pirimidos(5, 4-g)pteridina.
JP4520569B2 (ja) 2000-02-18 2010-08-04 照彦 豊岡 拡張型心筋症の遺伝子治療剤
US6303830B1 (en) * 2000-03-15 2001-10-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
AU2001284794A1 (en) * 2000-08-09 2002-02-18 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and uses therefor
PT2332582E (pt) * 2002-06-19 2014-01-28 Apeiron Biologics Ag Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão

Also Published As

Publication number Publication date
SI1515752T1 (sl) 2009-06-30
US20050251873A1 (en) 2005-11-10
CN101961493A (zh) 2011-02-02
EP1515752A1 (de) 2005-03-23
CA2489873C (en) 2016-08-09
EP2332582B1 (de) 2013-10-30
DE60324925D1 (de) 2009-01-08
DK1515752T3 (da) 2009-03-23
SI2332582T1 (sl) 2014-03-31
PT1515752E (pt) 2009-03-05
US20120251520A1 (en) 2012-10-04
AU2003240331A1 (en) 2004-01-06
US20100311822A1 (en) 2010-12-09
CN1671425A (zh) 2005-09-21
EP1515752B1 (de) 2008-11-26
DK2332582T3 (da) 2014-01-20
WO2004000367A1 (en) 2003-12-31
EP2047867B1 (de) 2013-05-22
AU2003240331B2 (en) 2008-08-21
ES2443305T3 (es) 2014-02-18
CN1671425B (zh) 2013-07-10
CA2489873A1 (en) 2003-12-31
ES2424971T3 (es) 2013-10-10
JP2006504637A (ja) 2006-02-09
ES2318137T3 (es) 2009-05-01
EP2332582A1 (de) 2011-06-15
EP2047867A1 (de) 2009-04-15
JP4598518B2 (ja) 2010-12-15
US8211426B2 (en) 2012-07-03
PT2332582E (pt) 2014-01-28
CY1108829T1 (el) 2014-04-09
US8802084B2 (en) 2014-08-12
US7794707B2 (en) 2010-09-14

Similar Documents

Publication Publication Date Title
ATE415175T1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE330038T1 (de) Nukleinsäure-biosensor
DE60041940D1 (de) Oligonukleotidprimer zur effizienten Detektion von Hepatitis C Virus (HCV) sowie Verwendungsverfahren
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
DE60035719D1 (de) Vorrichtung zur ermittlung von herzrate und anormaler beatmung
ITRM20050068A1 (it) Metodo per la rivelazione di acidi nucleici di agenti patogeni batterici o di parassiti nelle urine.
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60304755D1 (de) Vorrichtung zur Bestimmung von Thrombosen tiefliegender Venen
ATE438737T1 (de) Verfahren für den nachweis von erkrankungen
ATE405675T1 (de) Nukleinsäureliganden von tenascin-c
AU5641401A (en) Method for detecting and identifying the presence of biological substances derived from birds, and oligonucleotides therefor
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
CY1110138T1 (el) Προσδιορισμος υψηλης διεκπεραιωτικοτητας της δραστικοτητας lp-pla2
DE502004010500D1 (de) Vorrichtung zur koagulation von gewebe
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
DE60300341D1 (de) Vorrichtung zur Behandlung von Abgas
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE60312671D1 (de) Verfahren zum nachweis und zur lokalisierung von blutspuren und verbindung zum nachweis von blutspuren
DE60301283D1 (de) Verfahren zur Bestimmung von Biopolymeren
DE602004030036D1 (de) Multiplexanalyse von Nukleinsäuren zur Bestimmung von Genotypen des humanen Papillomavirus
NO20043438L (no) Etterproving av fiskeopprinnelse basert pa nukleinsyremonstergjenkjennelse
DE60324819D1 (de) Verfahren zur amplifikation von nukleinsäure, kit zur amplifikation von nukleinsäure, verfahren zum nachweis von einzelnukleotid-polymorphismus und reagentienkit zum nachweis von einzelnukleotid-polymorphismus
DE602004026067D1 (de) Gerät zur Behandlung von Füßen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1515752

Country of ref document: EP